Wilson Sonsini Goodrich & Rosati has advised Oak Hill Bio on IP matters. Cooley has advised Research Alliance Corporation III (RACC). OHB Pediatrics Ltd., operating as...
Oak Hill Bio and RACC Announce $175 Million Business Combination to Form Nasdaq-Listed Rare Disease Company
SonoThera Secures $125 Million in Oversubscribed Series B Financing
Wilson Sonsini Goodrich & Rosati has advised SonoThera. SonoThera has announced the successful closing of an oversubscribed $125 million Series B financing round. The proceeds from...
Oak Hill Bio Raises $32.5 Million in Series A Financing
Wilson Sonsini Goodrich & Rosati has advised Oak Hill Bio on patent matters related to the transaction. Oak Hill Bio, a clinical-stage rare disease therapeutics company,...
UCB to Acquire Candid Therapeutics in $2.2 Billion Deal
Cooley and Wilson Sonsini Goodrich & Rosati have advised Candid Therapeutics. Covington & Burling has represented UCB. UCB, a global biopharmaceutical company, has announced a definitive...
Rallybio to Acquire Candid Therapeutics in Merger and $505 Million Financing
Ropes & Gray has advised Rallybio. Wilson Sonsini Goodrich & Rosati has advised Candid Therapeutics on patent matters. Rallybio Corporation and Candid Therapeutics have entered into...
Predicta Biosciences Completes $23.4 Million Series A Financing Round
Wilson Sonsini Goodrich & Rosati has advised Predicta Biosciences. Predicta Biosciences, a precision oncology company focused on developing novel diagnostic and therapeutic discovery solutions, has announced...
Oak Hill Bio’s License Agreement with Roche
Wilson Sonsini Goodrich & Rosati advised Oak Hill Bio on patent matters related to the transaction. Oak Hill Bio, a biotechnology company focused on acquiring and...
Candid Therapeutics’ Agreement with WuXi Biologics
Wilson Sonsini Goodrich & Rosati advised Candid Therapeutics on the transaction. Candid Therapeutics, Inc., a clinical-stage biotechnology company focused on becoming the leader in advancing T-cell...
Janux Therapeutics’ $350 Million Common Stock Offering
Cooley advised Janux Therapeutics, and Wilson Sonsini Goodrich & Rosati advised the company on patent matters related to the transaction, while Latham & Watkins advised the...
Third Arc Bio’s $165 Million Series A Financing Round
Wilson Sonsini Goodrich & Rosati advised Vida Ventures on IP matters related to the transaction. Third Arc Bio Inc., a biotech company, announced a $165 million...
Janux Therapeutics’ $296.5 Million Common Stock Offering
Cooley advised Janux Therapeutics on the offering and Wilson Sonsini Goodrich & Rosati advised Janux on patent matters. Latham & Watkins advised the underwriters. Janux Therapeutics,...
CG Oncology’s $105 Million Financing Round
Wilson Sonsini Goodrich & Rosati advised Foresite Capital on the transaction. CG Oncology, Inc. announced the close of an oversubscribed $105 million crossover financing round, co-led...